Patents by Inventor Aimee Edinger

Aimee Edinger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Drug Formulations and Methods of Treatment for Metabolic Disorders
    Publication number: 20220409617
    Abstract: Methods of treatment of metabolic disorders with various compounds are provided. Subjects having a metabolic can be administered a sphingolipid-like compound, an ARF6 antagonist, or a PIKfyve antagonist. Formulations and medicaments are utilized to formulate therapeutics that can be administered to individuals as pharmaceutically effective salt or in pure form, including, but not limited to, formulations for oral, intravenous, or intramuscular administration.
    Type: Application
    Filed: November 13, 2020
    Publication date: December 29, 2022
    Applicant: The Regents of the University of California
    Inventor: Aimee Edinger
  • Synthetic Cytotoxic Molecules, Drugs, Methods of Their Synthesis and Methods of Treatment
    Publication number: 20210261583
    Abstract: Small molecules compounds and methods of their synthesis are provided. Formulations and medicaments are also provided that are directed to the treatment of disease, such as, for example, neoplasms, cancers, and other diseases. Therapeutics are also provided containing a therapeutically effective dose of one or more small molecule compounds, present either as pharmaceutically effective salt or in pure form, including, but not limited to, formulations for oral, intravenous, or intramuscular administration.
    Type: Application
    Filed: June 14, 2019
    Publication date: August 26, 2021
    Applicants: The Regents of the University of California, Universite de Montreal
    Inventors: Aimee Edinger, Stephen Hanessian
  • Synthetic sphingolipid-like molecules, drugs, methods of their synthesis and methods of treatment
    Patent number: 10995068
    Abstract: Small molecules comprised of azacyclic constrained sphingolipid-like compounds and methods of their synthesis are provided. Formulations and medicaments are also provided that are directed to the treatment of disease, such as, for example, neoplasms, cancers, and other diseases. Therapeutics are also provided containing a therapeutically effective dose of one or more small molecule compounds, present either as pharmaceutically effective salt or in pure form, including, but not limited to, formulations for oral, intravenous, or intramuscular administration.
    Type: Grant
    Filed: September 26, 2016
    Date of Patent: May 4, 2021
    Assignees: The Regents of the University of California
    Inventors: Aimee Edinger, Stephen Hanessian
  • Synthetic Sphingolipid-Like Molecules, Drugs, Methods of Their Synthesis and Methods of Treatment
    Publication number: 20180265464
    Abstract: Small molecules comprised of azacyclic constrained sphingolipid-like compounds and methods of their synthesis are provided. Formulations and medicaments are also provided that are directed to the treatment of disease, such as, for example, neoplasms, cancers, and other diseases. Therapeutics are also provided containing a therapeutically effective dose of one or more small molecule compounds, present either as pharmaceutically effective salt or in pure form, including, but not limited to, formulations for oral, intravenous, or intramuscular administration.
    Type: Application
    Filed: September 26, 2016
    Publication date: September 20, 2018
    Applicants: The Regents of the University of California, The Université de Montréal
    Inventors: Aimee Edinger, Stephen Hanessian
  • Azacyclic constrained analogs of FTY720
    Patent number: 10077236
    Abstract: Small molecules comprised of azacyclic constrained analogs of FTY720 are provided. Formulations and medicaments are also provided that are directed to the treatment of disease, such as, for example, leukemia, and other diseases. Therapeutics are also provided containing a therapeutically effective dose of one or more small molecule compounds, present either as pharmaceutically effective salt or in pure form, including, but not limited to, formulations for oral, intravenous, or intramuscular administration.
    Type: Grant
    Filed: July 15, 2014
    Date of Patent: September 18, 2018
    Assignees: The Regents of the University of California, The Université de Montréal
    Inventors: Aimee Edinger, Stephen Hanessian
  • AZACYCLIC CONSTRAINED ANALOGS OF FTY720
    Publication number: 20160159739
    Abstract: Small molecules comprised of azacyclic constrained analogs of FTY720 are provided. Formulations and medicaments are also provided that are directed to the treatment of disease, such as, for example, leukemia, and other diseases. Therapeutics are also provided containing a therapeutically effective dose of one or more small molecule compounds, present either as pharmaceutically effective salt or in pure form, including, but not limited to, formulations for oral, intravenous, or intramuscular administration.
    Type: Application
    Filed: July 15, 2014
    Publication date: June 9, 2016
    Inventors: Aimee Edinger, Stephen Hanessian